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T604N mutation increases CSF3R dimerization 
(A) Schematic of co-immunoprecipitation 
experiment to quantitate CSF3R dimerization. 
(B) The T640N mutation has increased 
dimerization relative to WT CSF3R. Flag and 
V5-tagged CSF3R constructs are co-transfected 
into cells, then an antibody to flag is used to 
immunoprecipitate CSF3R complexes. Co-
immunoprecipitated V5 tagged CSF3R is 
detected by immunoblotting and is normalized to 
the input. 
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Cancer is the second leading cause of death in the U.S.A. with over 1.5 million individuals being 
diagnosed every year. While cancer is often discussed as a single disease, it is an expansive and 
diverse set of diseases each requiring a unique treatment. In the face of these staggering numbers 
of patients and pathologies, rare cancers are often overlooked due to challenges in funding. 
Recruiting sufficient numbers of patient samples for clinical trials presents another challenge. 
Chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) are two such 
rare cancers; they are characterized by high levels of neutrophils or neutrophil precursors and lack 
molecular signatures seen in most CML patients, such as BCR-ABL1 fusion, or rearrangements of 
PDGFR or FGFR. Instead, recent studies have identified colony stimulating factor 3 receptor 
(CSF3R) as a common oncogenic driver in CNL affecting approximately 80% of patients. In these 
December 20, 2015 SCIENCE SPOTLIGHT 
 
2 Volume 5, Issue 12 | Fred Hutchinson Cancer Research Center 
 
patients the most common mutation is a substitution, T618I, which is sufficient to drive oncogenesis 
in multiple in vitro models. This mutation causes ligand-independent dimerization of CSF3R and 
results in constitutive signal transduction through the JAK pathway. CSF3R bearing the T618I 
mutation is also hypo-glycosylated, however, the relationship between glycosylation and 
dimerization remains unknown. 
In a recent study published in Clinical Cancer Research, Dr. Julia Maxson, a postdoctoral fellow in 
the Radich Laboratory (Clinical Research Division), identified a CSF3R mutation that has never been 
observed in CNL and aCML patients. Sequencing the CSF3R gene in two patient samples revealed 
the mutation, T640N, which was first identified in rare cases of AML. While this study focused on 
findings in CNL and aCML, Dr. Maxson has observed this mutation in other cancer types, "I'm also 
collaborating with Soheil Meshinchi on a project looking at CSF3R mutations in pediatric AML. 
Interestingly, the CSF3R T640N mutation was also found in two of these patients." In the current 
study the authors demonstrated that the T640N conferred many oncogenic behaviors to 
hematopoietic cells including the ability to grow independent of cytokine stimulation, and colony 
formation independent of the CSF3R ligand. These results suggested that T640N was acting 
through the same mechanism as the common T618I mutation –  ligand independent dimerization. 
Molecular modeling from a previous publication predicted the T640N mutation would drive 
dimerization through increased hydrogen bonding. As predicted, the mutation increased ligand-
independent receptor dimerization, however, this unique mutation provided a novel insight into the 
relationship of glycosylation and dimerization. T640N, unlike T618I, resides in the transmembrane 
region of CSF3R, which should preclude any physical interaction with glycosyltransferase enzymes. 
Interestingly, just like the common T618I mutation, T640N also decreased total levels of 
glycosylation on CSF3R. These findings raise the possibility that decreased glycosylation is a result 
of increased receptor dimerization, where glycoslytransferases are sterically occluded from the 
residues they normal act on. 
These researchers verified the oncogenic nature of the T640N mutation in a mouse leukemia model, 
demonstrating that at the pathological level it behaved equivalent to the T618I mutation. Cells 
harboring the T618I mutation in CSF3R are known to activate the Janus Kinase (JAK) protein family, 
and these cells demonstrate sensitivity to JAK inhibitors. Excitingly, the authors find that the T640N 
mutation induces a greater sensitivity to this class of inhibitors. This work makes a strong case for 
using both mutations as biomarkers to identify patients who will respond well to JAK inhibitors, 
however, such clinical studies have not yet been performed. 
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The use of personalized genetic analysis to improve treatment options is a common theme in Dr. 
Maxson's research. In a soon to be published article in Cancer Research, she uses these 
approaches to identify new therapeutic targets for leukemia and expand those findings into solid 
tumors. This work is among a new class, demonstrating that personalized medicine cannot rely only 
on genomic and expression data sets, but must also be approached with a functional perspective.  
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